MRSA Bacteremia: recent epidemiological and therapeutical trends;Bactériémies à Staphylococcus aureus résistant à la méthicilline : aspects épidémiologiques et thérapeutiques récents

Revue de Medecine Interne

Volumn 28, Issue 11, 2007, Pages 746-755

  Forestier, E ^a   Remy V ^a   Mohseni Zadeh, M ^a   Lesens, O ^b   Jauhlac, B ^c   Christmann, D ^a   Hansmann, Y ^a  

^a Service de médecine interne et maladies infectieuses et tropicales   (France)

^b HÔTEL DIEU   (France)

^c Institut de Bacteriologie   (France)

Author keywords

Antibiotic treatment; Bacteremia; Isolation; Nosocomial infection; Screening; Staphylococcus aureus

Indexed keywords

CEFOXITIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; MINOCYCLINE; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2ALPHA; PENICILLIN G; PRISTINAMYCIN; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BLOOD TOXICITY; CLINICAL RESEARCH; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PREVALENCE; SHORT SURVEY; TREATMENT OUTCOME;

BACTEREMIA; BACTERIAL PROTEINS; CROSS INFECTION; EUROPE; FRANCE; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PENICILLIN-BINDING PROTEINS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 35448951331     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.11.014     Document Type: Short Survey

References (64)

1. Wang F., Zhu D., and Hu F. Surveillance of bacterial resistance in Shanghai. Zhonghua Yi Xue Za Zhi 81 (2001) 17-19
2. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50 (2004) 59-69
3. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39 (2004) 309-317
4. Kesah C., Ben Redjeb S., Odugbemi T.O., Boye C.S., Dosso M., Ndinya Achola J.O., et al. Prevalence of methicillin-resistant Staphylococcus aureus in eight African hospitals and Malta. Clin. Microbiol. Infect. 9 (2003) 153-156
5. Tiemersma E.W., Bronzwaer S.L., Lyytikainen O., Dejener J.E., Schrijnemakers P., Bruinsma N., et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg. Infect. Dis. 10 (2004) 1627-1634
6. Bussy-Malgrange V., and Jebabli M. Surveillance des bactériémies nosocomiales en France. Résultats 2002 (2003), Institut de Veille Sanitaire
7. Voss A., Milatovic D., Wallrauch-Schwarz C., Rosdahl V.T., and Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 13 (1994) 50-55
8. van der Mee-Marquet N., Domelier A.S., Girard N., and Quentin R. Epidemiology and typing of Staphylococcus aureus strains isolated from bloodstream infections. J. Clin. Microbiol. 42 (2004) 5650-5657
9. Goossens H., Ferech M., Vander Stichele R., and Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365 (2005) 579-587
10. Muller A.A., Mauny F., Bertin M., Cornette C., Lopez-Lozano J.M., Viel J.F., et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin. Infect. Dis. 36 (2003) 971-978
11. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., and Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 9 (2003) 1415-1422
12. Landman D., Chockalingam M., and Quale J.M. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin. Infect. Dis. 28 (1999) 1062-1066
13. Dziekan G., Hahn A., Thune K., Schwarzer G., Schafer K., Daschner F.D., et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J. Hosp. Infect. 46 (2000) 263-270
14. Shlaes D.M., Gerding D.N., John Jr. J.F., Craig W.A., Bornstein D.L., Duncan R.A., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25 (1997) 584-599
15. Pittet D., Hugonnet S., Harbarth S., Mourouga P., Sauvan V., Touveneau S., et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 356 (2000) 1307-1312
16. Cooper B.S., Stone S.P., Kibbler C.C., Cookson B.D., Roberts J.A., Medley G.F., et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technol. Assess. 7 (2003) 1-194
17. Girou E., Pujade G., Legrand P., Cizeau F., and Brun-Buisson C. Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin. Infect. Dis. 27 (1998) 543-550
18. Lodise Jr. T.P., McKinnon P.S., and Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect. Control Hosp. Epidemiol. 24 (2003) 655-661
19. Wertheim H.F., Vos M.C., Ott A., van Belkum A., Voss A., Kluytmans J.A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364 (2004) 703-705
20. Pujol M., Pena C., Pallares R., Ariza J., Ayats J., Dominguez M.A., et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am. J. Med. 100 (1996) 509-516
21. Steinberg J.P., Clark C.C., and Hackman B.O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin. Infect. Dis. 23 (1996) 255-259
22. Lodise T.P., and McKinnon P.S. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 52 (2005) 113-122
23. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg. Infect. Dis. 7 (2001) 178-182
24. Zetola N., Francis J.S., Nuermberger E.L., and Bishai W.R. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect. Dis. 5 (2005) 275-286
25. Salgado C.D., Farr B.M., and Calfee D.P. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. 36 (2003) 131-139
26. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
27. Tacconelli E., Carmeli Y., Aizer A., Ferreira G., Foreman M.G., and D'Agata E.M. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin. Infect. Dis. 37 (2003) 1629-1638
28. Johnson D.W., MacGinley R., Kay T.D., Hawley C.M., Campbell S.B., Isbel N.M., et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol. Dial. Transplant. 17 (2002) 1802-1807
29. Lok C.E., Stanley K.E., Hux J.E., Richardson R., Tobe S.W., and Conly J. Hemodialysis infection prevention with polysporin ointment. J. Am. Soc. Nephrol. 14 (2003) 169-179
30. Chatzinikolaou I., Finkel K., Hanna H., Boktour M., Foringer J., Ho T., et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am. J. Med. 115 (2003) 352-357
31. Dogra G.K., Herson H., Hutchison B., Irish A.B., Health C.H., Golledge C., et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J. Am. Soc. Nephrol. 13 (2002) 2133-2139
32. Conférence de consensus de la Société Française d'Anesthésie et Réanimation. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie. Actualisation 1999.
33. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 36 (2003) 53-59
34. Fowler Jr. V.G., Justice A., Moore C., Benjamin D.K., Woods C.W., Campbell S., et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40 (2005) 695-703
35. Soriano A., Martinez J.A., Mensa J., Marco F., Almela M., Moreno-Martinez A., et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin. Infect. Dis. 30 (2000) 368-373
36. Roghmann M.C. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch. Intern. Med. 160 (2000) 1001-1004
37. Jensen A.G., Wachmann C.H., Espersen F., Scheibel J., Skinhoj P., and Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch. Intern. Med. 162 (2002) 25-32
38. Blot S.I., Vandewoude K.H., Hoste E.A., and Colardyn F.A. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. 162 (2002) 2229-2235
39. Lodise T.P., McKinnon P.S., Swiderski L., and Rybak M.J. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36 (2003) 1418-1423
40. Lesens O., Hansmann Y., Brannigan E., Remy V., Hopkins S., Martinot M., et al. Positive surveillance blood culture is a predictive factor for secondary metastatic infection in patients with Staphylococcus aureus bacteraemia. J. Infect. 48 (2004) 245-252
41. Fowler Jr. V.G., Sanders L.L., Sexton D.J., Kong L., Marr K.A., Gopal A.K., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin. Infect. Dis. 27 (1998) 478-486
42. Melzer M., Eykyn S.J., Gransden W.R., and Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin. Infect. Dis. 37 (2003) 1453-1460
43. Fowler Jr. V.G., Li J., Corey G.R., Boley J., Marr K.A., Gopal A.K., et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J. Am. Coll. Cardiol. 30 (1997) 1072-1078
44. Romero-Vivas J., Rubio M., Fernandez C., and Picazo J.J. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 21 (1995) 1417-1423
45. Lentino J.R., Baddour L.M., Wray M., Wong E.S., and Yu V.L. Staphylococcus aureus and other bacteremias in hemodialysis patients: antibiotic therapy and surgical removal of access site. Infection 28 (2000) 355-360
46. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42 (2004) 2398-2402
47. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., and Moellering Jr. R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38 (2004) 1700-1705
48. Fowler Jr. V.G., Sakoulas G., McIntyre L.M., Meka V.G., Arbeit R.D., Cabell C.H., et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J. Infect. Dis. 190 (2004) 1140-1149
49. Ferry T., Thomas D., Genestier A.L., Bes M., Lina G., Vandenesch F., et al. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin. Infect. Dis. 41 (2005) 771-777
50. Mylotte J.M., McDermott C., and Spooner J.A. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev. Infect. Dis. 9 (1987) 891-907
51. Ringberg H., Thoren A., and Lilja B. Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 28 (2000) 132-136
52. Fowler Jr. V.G., Olsen M.K., Corey G.R., Woods C.W., Cabell C.H., Reller L.B., et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch. Intern. Med. 163 (2003) 2066-2072
53. Chang F.Y., MacDonald B.B., Peacock Jr. J.E., Musher D.M., Triplett P., Mylotte J.M., et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 82 (2003) 322-332
54. Fluit A.C., Wielders C.L., Verhoef J., and Schmitz F.J. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J. Clin. Microbiol. 39 (2001) 3727-3732
55. Decousser J.W., Pina P., Picot F., Delalande C., Pangon B., Courvalin P., et al. Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey. J. Antimicrob. Chemother. 51 (2003) 1213-1222
56. Song J.H., Hiramatsu K., Suh J.Y., Ko K.S., Ito T., Kapi M., et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 48 (2004) 4926-4928
57. Cartolano G.L., Cheron M., Benabid D., Leneveu M., and Boisivon A. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin. Microbiol. Infect. 10 (2004) 448-451
58. Gemmell C.G., Edwards D.I., Fraise A.P., Gould F.K., Ridgway G.L., and Warren R.E. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57 (2006) 589-608
59. Small P.M., and Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34 (1990) 1227-1231
60. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115 (1991) 674-680
61. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45 (2001) 2460-2467
62. Darley E.S., and MacGowan A.P. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin. Microbiol. Infect. 10 (2004) 62-69
63. Cantu T.G., Yamanaka-Yuen N.A., and Lietman P.S. Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. 18 (1994) 533-543
64. Falagas M.E., Manta K.G., Ntziora F., and Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother (2006)